+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Rare Hemophilia Factors Market - Growth, Trends, and Forecasts (2020 - 2025)

  • ID: 5176679
  • Report
  • August 2020
  • Region: Global
  • 111 pages
  • Mordor Intelligence
UP TO OFF
until Dec 31st 2020
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Baxter International Inc.
  • Bayer AG
  • Biogen Inc.
  • CSL Behring
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • MORE
There are certain factors that are driving the market growth include rising adoption and approval of new treatment techniques, a growing number of government initiatives, and funding.

Similarly, According to the Global Hemophilia Care 2019 report, more than 1,125,000 men around the world have an inherited bleeding disorder and 418,000 of those who have a severe version of the most undiagnosed disease. And about 400,000 people globally were estimated to have hemophilia.​

Scientists have reported that hemophilia is three times more prevalent in men worldwide than previously thought and still associated with a poorer life expectancy, especially in low-income countries. Therefore the increase of hemophilia is associated with the increasing demand for Rare Hemophilia Factors Market.

Key Market Trends

Fresh frozen plasma (FFP) is Expected to Hold Significant Market Share in the Treatment Segment

Plasma transfusion is indicated for the management of bleeding or to prevent bleeding prior to an urgent invasive procedure in patients requiring replacement of multiple coagulation factors. Fresh frozen plasma is the fluid portion of a unit of whole blood that is frozen in a designated time frame, usually within 8 hours. FFP contains all coagulation factors except platelets. FFP contains fibrinogen (400 to 900 mg/unit), albumin, protein C, protein S, antithrombin, tissue factor pathway inhibitor. FFP can only be administered intravenously. FFP must be ABO compatible with the recipient’s red cells. The FFP container and fluid upon visual inspection should have no leakage, clots, or abnormal color.

North America Dominates the Market and Expected to do Same in the Forecast Period

According to the Center for Disease Control and Prevention (CDC), hemophilia A occurs in 1 in 5,000 live male births. Hemophilia A is about four times as common as hemophilia B. The number of people with hemophilia in the United States is estimated to be about 20,000 individuals (National Hemophilia Foundation, 2018).

In the United States, most people with hemophilia are diagnosed at a very young age. Based on CDC data, the median age at diagnosis is 36 months for people with mild hemophilia, 8 months for those with moderate hemophilia, and 1 month for those with severe hemophilia. In about two-thirds of cases, there is a family history of hemophilia. The diagnosis of hemophilia is made using a special blood test and most babies can be tested soon after birth. Sometimes prenatal genetic testing is done to diagnose hemophilia before birth (CDC, 2019).

Competitive Landscape

The global Rare Hemophilia Factors market is moderately competitive and consists of a number of major players. The companies like Baxter Healthcare, Bayer Healthcare, Bio Products Laboratory Ltd., Biogen, CSL Behring, Novo Nordisk, Pfizer, Inc., Takeda Pharmaceutical Co. Ltd., among others, hold the substantial market share in the Rare Hemophilia Factors market.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Baxter International Inc.
  • Bayer AG
  • Biogen Inc.
  • CSL Behring
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Adoption and Approval of New Treatment Techniques
4.2.2 Growing Number of Government Initiatives and Funding
4.3 Market Restraints
4.3.1 High Cost of Treatment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Treatment
5.1.1 Factor Concentrate
5.1.2 Fresh frozen plasma (FFP)
5.1.3 Cryoprecipitate
5.1.4 Others
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Baxter International Inc.
6.1.2 Bayer AG
6.1.3 Bio Products Laboratory Ltd.
6.1.4 Biogen Inc.
6.1.5 CSL Behring
6.1.6 Novo Nordisk A/S
6.1.7 Pfizer, Inc.
6.1.8 Takeda Pharmaceutical Co. Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Baxter International Inc.
  • Bayer AG
  • Bio Products Laboratory Ltd.
  • Biogen Inc.
  • CSL Behring
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • Takeda Pharmaceutical Co. Ltd.
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll